Anixa Biosciences Long-Term Debt 2011-2026 | ANIX

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Anixa Biosciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
163 K	203 K	123 K	175 K	220 K	-	-	-	-	-	-	-	5.55 M	32.3 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
5.55 M	32.3 K	924 K

Quarterly Long-Term Debt Anixa Biosciences

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
151 K	163 K	174 K	184 K	-	203 K	213 K	93 K	108 K	123 K	136 K	149 K	209 K	175 K	187 K	202 K	-	220 K	-	220 K	40.8 K	-	10.6 K	26 K	-	55.2 K	-	55.2 K	-	-	-	-	-	-	-	-	-	-	-	-	370 K	370 K	-	-	1.51 M	-	1.76 M	1.63 M	408 K	549 K	549 K	549 K	-	32.3 K	32.3 K	32.3 K	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.76 M	10.6 K	320 K

Long-Term Debt of other stocks in the Diagnostics research industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	15.6 M	-	-6.23 %	$ 30.6 M	Germany
Aspira Women's Health AWH	1.04 M	-	-6.19 %	$ 10.5 M	USA
Agilent Technologies A	2.73 B	$ 116.83	2.6 %	$ 35.5 B	USA
Biocept BIOC	1.2 M	-	-13.05 %	$ 7.29 M	USA
DermTech DMTK	38 K	-	-11.32 %	$ 2.94 M	USA
Enzo Biochem ENZ	189 K	-	-8.98 %	$ 14.8 K	USA
Castle Biosciences CSTL	9.74 M	$ 25.13	1.19 %	$ 698 M	USA
Exact Sciences Corporation EXAS	6.4 M	-	-	$ 19.8 B	USA
Danaher Corporation DHR	18.4 B	$ 196.66	2.95 %	$ 140 B	USA
CareDx, Inc CDNA	19.7 M	$ 18.02	1.98 %	$ 960 M	USA
Oxford Immunotec Global PLC OXFD	32 K	-	-	$ 562 M	Britain
DexCom DXCM	53.8 M	$ 65.77	4.21 %	$ 25.7 B	USA
Akumin AKU	1.25 B	-	-17.87 %	$ 25.9 M	Canada
Fulgent Genetics FLGT	360 K	$ 16.25	2.14 %	$ 491 M	USA
Heska Corporation HSKA	307 K	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	546 K	-	-20.0 %	$ 1.06 M	USA
Burning Rock Biotech Limited BNR	18.3 M	$ 15.84	-1.55 %	$ 170 M	China
Guardant Health GH	1.5 B	$ 94.49	1.28 %	$ 11.8 B	USA
Co-Diagnostics CODX	574 K	$ 4.4	101.83 %	$ 5.85 M	USA
Accelerate Diagnostics AXDX	782 K	-	-61.36 %	$ 2.46 M	USA
Global Cord Blood Corporation CO	147 K	-	-	$ 399 M	China
Fluidigm Corporation FLDM	54.2 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	388 K	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	5.49 M	-	0.12 %	$ 80.1 M	China
Charles River Laboratories International CRL	2.14 B	$ 176.18	3.87 %	$ 8.73 B	USA
PRA Health Sciences, Inc. PRAH	1.16 B	-	-	$ 10.7 B	USA
Motus GI Holdings MOTS	1.24 M	-	-34.28 %	$ 263 K	Israel
Biodesix BDSX	40 M	$ 14.28	-1.72 %	$ 1.85 B	USA
ICON Public Limited Company ICLR	3.4 B	$ 108.06	0.84 %	$ 8.91 B	Irlanda
Interpace Biosciences IDXG	752 K	$ 1.99	-0.25 %	$ 8.8 M	USA
OpGen OPGN	1.85 M	-	-16.95 %	$ 1.54 M	USA
Illumina ILMN	554 M	$ 128.36	1.52 %	$ 20.4 B	USA
PerkinElmer PKI	2.63 B	-	-0.91 %	$ 14.7 B	USA
IQVIA Holdings IQV	13.9 B	$ 174.45	2.3 %	$ 30 B	USA
Quotient Limited QTNT	145 M	-	-11.32 %	$ 1.1 M	Schweiz
QIAGEN N.V. QGEN	1.65 B	-	-	$ 10.6 B	Niderland
Laboratory Corporation of America Holdings LH	5.08 B	$ 275.15	2.22 %	$ 22.9 B	USA
Lantheus Holdings LNTH	569 M	$ 80.09	2.57 %	$ 5.41 B	USA
Biomerica BMRA	100 K	$ 2.16	-	$ 4.96 M	USA
BioNano Genomics BNGO	3.48 M	$ 1.17	0.02 %	$ 6.37 M	USA
Medpace Holdings MEDP	114 M	$ 523.59	2.96 %	$ 15.1 B	USA
Mettler-Toledo International MTD	2.09 B	$ 1 323.64	4.22 %	$ 27.3 B	Schweiz
Myriad Genetics MYGN	120 M	$ 4.86	2.43 %	$ 450 M	USA
Celcuity CELC	138 M	$ 116.44	0.76 %	$ 5.44 B	USA
NeoGenomics NEO	342 M	$ 8.3	2.98 %	$ 1.06 B	USA
Neogen Corporation NEOG	875 M	$ 10.53	5.46 %	$ 2.28 B	USA
Natera NTRA	282 M	$ 211.61	1.12 %	$ 20.8 B	USA
National Research Corporation NRC	75 M	$ 17.63	3.43 %	$ 395 M	USA